Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD-1 Inhibitors (Camrelizumab) Combined With VEGF Inhibitors (Apatinib) for Locally Advanced dMMR/MSI-H Colorectal Cancer: an Open-label, Multi-center, Phase II Clinical Trial

Next Previous
X
Search
Trial Profile

PD-1 Inhibitors (Camrelizumab) Combined With VEGF Inhibitors (Apatinib) for Locally Advanced dMMR/MSI-H Colorectal Cancer: an Open-label, Multi-center, Phase II Clinical Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Capecitabine; Oxaliplatin
  • Indications Carcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Jul 2024 Planned End Date changed from 31 Dec 2024 to 31 Jul 2025.
    • 28 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
    • 28 Jan 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top